Pacific Biosciences of California, Inc. (PACB)
Lost Money on Pacific Biosciences of California, Inc.(PACB)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Shareholders With Losses In Pacific Biosciences Of California Inc Are Invited To Join A Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences: Cash Rich, Revenue Poor, Still A 'Sell'
PacBio's Q2 2024 revenue dropped 24% YoY, primarily due to a sharp decline in instrument sales. Gross margin plummeted to 16%, reflecting increased costs and pricing pressures in a challenging market. Rising SG&A expenses, including employee separation costs, are pressuring PacBio's already weakened financials.
Pacific Biosciences of California, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - PACB
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing
A weak funding environment for life sciences tools has PacBio trading back below $2, as the company has come in well below prior revenue expectations and taken down mid-term targets. PacBio's Q2 was weaker than expected after a big miss-and-lower Q1, with instrument placements and revenue down sharply and consumables revenue impacted by weak utilization tied to customer budget limitations. PacBio's technology works, and the latest iteration performs well in terms of throughput, ease of use, and accuracy, but valid questions remain as to whether it can thrive (or survive).
Investors In Pacific Biosciences Of California Inc Are Encouraged To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
PACB ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Pacific Biosciences of California, Inc.
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Shareholders With Losses In Pacific Biosciences Of California Inc Invited To Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences of California, Inc. (PACB) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacific Biosciences of California, Inc. ("Pacific Biosciences of California, Inc.") (NASDAQ:PACB) concerning possible violations of federal securities laws. On April 16, 2024, PACB preannounced poor Q1 2024 top-line results and then announced a significant reduction in its full-year guidance for 2024 as well as a reconsideration of their long-term guidance for fiscal year 2026.
Pacific Biosciences Of California Inc Investors Encouraged To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences Of California Inc Stockholders Invited To Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences Of California Inc Investors Eligible To Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
